KS SMART MGMT (08181) issues profit warning, expects interim loss attributable to owners of the company of approximately HK$11 million
KS SMART MGMT (08181) announces that the group is expected to record a loss attributable to owners of the company of approximately HK$11 million for the six months ended 30 September 2026, compared with approximately HK$29.3 million for the six months ended 30 September 2025.
KS SMART MGMT (08181) announces that the Group is expected to record a loss attributable to owners of the Company of approximately HK$11 million for the six months ended September 30, 2026, compared with approximately HK$29.3 million for the six months ended September 30, 2025.
The Board considers that the decrease in loss was mainly due to a decrease in administrative expenses of approximately HK$24.4 million, primarily attributable to the absence of the following items: 1) one-off staff costs of HK$16 million incurred in the same period of 2025 for the smart monitoring system center established and commenced operations by the Group in June 2025; and 2) staff bonuses of HK$6.9 million in the same period of 2025; and a decrease in gross profit of approximately HK$3.4 million, mainly due to a decrease in revenue of approximately HK$5.4 million resulting from a decrease in the number of property management contracts, a decrease in gross profit of a PRC subsidiary of the Group, and an increase in depreciation of the smart monitoring system center during the period.
Related Articles

YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.
YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.






